Lesson plan
DSP-6745
DSP-6745 is a serotonergic agent which was under development for the treatment of psychotic disorders but was never marketed. It is taken orally. The drug acts as a serotonin reuptake inhibitor (SRI) and as an antagonist of the serotonin 5-HT 2A , 5-HT 2C , and 5-HT 7 receptors. Its affinities (K i ) were 0.653 nM for the serotonin transporter (SERT), 0.331 nM for the serotonin 5-HT 2A receptor, 1.34 nM for the serotonin 5-HT 2C receptor, and 31.7 nM for the serotonin 5-HT 7 receptor. Conversely, its or K b values were 0.753 nM at the SERT, 0.566 nM at the serotonin 5-HT 2A receptor, 1.37 nM at the serotonin 5-HT 2C receptor, and 2.12 nM at the serotonin 5-HT 7 receptor. It also shows lower affinity for a number of other receptors, such as the serotonin 5-HT 2B receptor (K i = 7.58 nM). DSP-6745 produces antidepressant-like, anxiolytic-like, antipsychotic-like, and pro-cognitive effects in animals. The chemical synthesis of DSP-6745 has been described. DSP-6745 was first described in the scientific literature by 2024. It was under development by Sumitomo Dainippon Pharma or Sumitomo Pharma. The drug reached phase 1 clinical trials for psychotic disorders prior to the discontinuation of its development in November 2022.
Article summary
DSP-6745 is a serotonergic agent which was under development for the treatment of psychotic disorders but was never marketed. It is taken orally. The drug acts as a serotonin reuptake inhibitor (SRI) and as an antagonist of the serotonin 5-HT 2A , 5-HT 2C , and 5-HT 7 receptors. Its affinities (K i ) were 0.653 nM for the serotonin transporter (SERT), 0.331 nM for the serotonin 5-HT 2A receptor, 1.34 nM for the serotonin 5-HT 2C receptor, and 31.7 nM for the serotonin 5-HT 7 receptor. Conversely, its or K b values were 0.753 nM at the SERT, 0.566 nM at the serotonin 5-HT 2A receptor, 1.37 nM at the serotonin 5-HT 2C receptor, and 2.12 nM at the serotonin 5-HT 7 receptor. It also shows lower affinity for a number of other receptors, such as the serotonin 5-HT 2B receptor (K i = 7.58 nM). DSP-6745 produces antidepressant-like, anxiolytic-like, antipsychotic-like, and pro-cognitive effects in animals. The chemical synthesis of DSP-6745 has been described. DSP-6745 was first described in the scientific literature by 2024. It was under development by Sumitomo Dainippon Pharma or Sumitomo Pharma. The drug reached phase 1 clinical trials for psychotic disorders prior to the discontinuation of its development in November 2022.
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.